mRNA Expression of Somatostatin Receptors (1-5) in MCF7 and MDA-MB231 Breast Cancer Cells
-
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.
-
Park’s textbook of Preventive And Social Medicine. K. Park. Twenty-second edition; 2013: Non- Communicable Diseases; Breast cancer; page. No; 359.
-
Rajini S, Kamesh C, Senthil VS. Knowledge of breast cancer and its risk factors among rural women of Puducherry – a cross-sectional study. JCRR 2015;07(19):60-64.
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-2917.
-
Kondov B, Milenkovikj Z, Kondov G, Petrushevska G, Basheska N, Bogdanovska-Todorovska M, et al. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. Maced J Med Sci 2018;6(6):961-967.
-
Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402–2412.
-
Hsu YL, Kuo PL, Lin LT, Lin CC. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J Pharmacol Exp Ther 2005;313:333-344.
-
Lahlou H, Saint-Laurent N, Esteve JP. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003;278:39356-39371.
-
Geredeli C. Comparison of Somatostatin and Famotidine for the Treatment of Nonvariceal Acute Upper Gastrointestinal Bleeding. Int J Curr Res Rev 2018;10(08):25-27.
-
Günther T, Tulip G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International union of basic and clinical pharmacology. CV. Somatostatin receptors: Structure, function, ligands, and new nomenclature. Pharmacol Rev 2018;70:763?835.
-
Day R, Dong W, Panetta R, Kraicer J, Greenwood MT, Patel YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double-labelling in situ hybridization analysis. Endocrinology 1995;136:5232?5235.
-
Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G. Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Dig Liver Dis 2004;36 Suppl 1:S8-16.
-
He Y, Yuan XM, Lei P, Wu S, Xing W, Lan XL, et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin 2009; 30:1053-1059.
-
Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal 2009;21:428-439.
-
Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008;22:2278-2292.
-
Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, et al. Octreotide promotes apoptosis in human somatotroph tumour cells by activating somatostatin receptor type 2. Endocr Relat Can 2006;13:955-962.
-
Somvanshi PK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 2009;21:1396-1414.
-
Florio T. Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases. Mol Cell Endocrinol 2008;286:40?48.
-
Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, et al. Molecular signalling of somatostatin receptors. Ann N Y Acad Sci 2004;1014:121-131.
-
Li M, Zhang R, Li F, Wan GH, Kim HJ, Becnel L, et al. Transfection of SSTR?1 and SSTR?2 Inhibits Panc?1 Cell proliferation and renders Panc?1 cells responsive to a somatostatin analogue. J Am Coll Surg 2005;201:571?578.
-
Watt HL, Kharmate G, Kumar U. Biology of somatostatin in breast cancer. Mol Cell Endocrinol 2008; 286:251-261.
-
Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001; 35:1-23.
-
Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 2001,54:641-649.
-
Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, et al. omatostatin receptors in primary human breast can-cer: quantitative analysis of mRNA for subtypes 1-5 andcorrelation with receptor protein expression and tumourpathology. Breast Cancer Res Treat 2005,92:175-186.
-
Marguerite M. Vantangoli, Samantha J. Madnick, Susan M. Huse, Paula Weston, and Kim Boekelheide. MCF-7 Human Breast Cancer Cells Form Differentiated Microtissues in Scaffold-Free Hydrogels. PLoS One 2015;10(8):e0135426.
-
Ali R, Samman N, Al Zahrani H, Nehdi A, Rahman S, Khan AL, et al. Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1. BMC Cancer 2017;17:803.
-
He Y, Yuan XM, Lei P, Wu S, Xing W, The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin 2009;30,1053-1059
-
Watt HL, Kumar U. Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell Int 2006;6:5.
-
Rivera JA, Alturaihi H, Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinogen 2005;4:10.
-
Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol 2014;10(14):2293-2301.
-
Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol 2012;86:1491-1504.
-
War SA, Kumar U. Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis. J Mol Signal 2012;7:5.
-
Pilichowska M, Kimura N, Schindler M, et al. Expression of somatostatin type 2A receptor correlates with estrogen receptor in human breast carcinoma. Endocr Pathol 2000;11:57-67.
-
Duran-Prado M, Gahete MD, Hergueta-Redondo M, Martínez-Fuentes AJ, Córdoba-Chacón J, Palacios J, et al. The new truncated somatostatin receptor variant sst5TMD4 is associated with poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012;31:2049-2061.
-
Reubi JC, Schonbrunn A. Illuminating somatostatin analogue action at neuroendocrine tumour receptors. Trends Pharmacol Sci 2013;34:676-688.
-
Cameron Smith M, Orlando C, Serio M, Maggi M. Somatostatin receptors and breast cancer. J Endocrinol Invest 2003;26:125–130.
-
Van Den Bossche B, Van Belle S, De Winter F, Signore A, van de Wiele C. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med 2006;47:6–13.
-
Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumour agents. Ann Oncol 2006;17:1733–1742.